Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.45 |
| ▸ | CHRNG | P07510 | 1/20 | 0.45 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.45 |
| ▸ | CHRND | Q07001 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31211792 | 0.93 | MMP2 (0.48) | MMP2CALCRLF2 | |
| SCHEMBL29424183 | 0.91 | MMP2 (0.61) | MMP2CALCRLOPRK1CHRNA1CHRNG | |
| SCHEMBL29630562 | 0.90 | MMP2 (0.55) | MMP2FOLH1 | |
| SCHEMBL30751950 | 0.90 | NAALAD2 (0.51) | OPRK1 | |
| SCHEMBL31170896 | 0.89 | GNPAT (0.56) | MMP2FOLH1OPRK1 | |
| SCHEMBL30507602 | 0.89 | GNPAT (0.56) | MMP2FOLH1OPRK1 | |
| SCHEMBL29531462 | 0.89 | MMP2 (0.56) | MMP2 | |
| SCHEMBL29590137 | 0.89 | MMP2 (0.58) | MMP2OPRK1 | |
| SCHEMBL29531641 | 0.89 | MMP2 (0.58) | MMP2OPRK1 | |
| SCHEMBL30434967 | 0.89 | MMP2 (0.51) | MMP2CALCRLOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630620-B2 | Anti-GDF15 neutralizing monoclonal antibody and use thereof | NUAGE (SHAANXI) MEDICAL AND TECHNOLOGY COMPANY LTD (CN) | 2026-05-19 | — | — | US | disclosed |
| US-20230203145-A1 | ANTI-GDF15 NEUTRALIZING MONOCLONAL ANTIBODY AND USE THEREOF | NUAGE (SHAANXI) MEDICAL AND TECHNOLOGY COMPANY LTD (CN) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630620-B2 | Anti-GDF15 neutralizing monoclonal antibody and use thereof | ARGLU1, ARG1, ISG15 | MMP2 3506/4885CALCRL 1082/4885F2 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.